JPMorgan Chase & Co. Issues Positive Forecast for Inspire Medical Systems (NYSE:INSP) Stock Price

Inspire Medical Systems (NYSE:INSP) had its price objective raised by equities research analysts at JPMorgan Chase & Co. from $60.00 to $65.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 5.09% from the stock’s previous close.

INSP has been the topic of a number of other reports. Mizuho set a $75.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, October 13th. UBS Group assumed coverage on Inspire Medical Systems in a research note on Tuesday, July 28th. They set a “sell” rating and a $39.00 target price for the company. Robert W. Baird increased their target price on Inspire Medical Systems from $73.00 to $77.00 and gave the stock a “neutral” rating in a research note on Tuesday. Stifel Nicolaus lifted their price target on Inspire Medical Systems from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Finally, Truist Financial restated a “hold” rating and issued a $76.00 price target (down from $78.00) on shares of Inspire Medical Systems in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $71.24.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP traded down $5.36 during trading on Tuesday, reaching $61.85. The company had a trading volume of 562,875 shares, compared to its average volume of 1,043,012. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The stock’s fifty day moving average price is $68.69 and its 200 day moving average price is $58.82. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 13.41, a price-to-earnings-growth ratio of 5.37 and a beta of 0.73.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $206.69 million for the quarter, compared to analyst estimates of $204.31 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. Inspire Medical Systems’s quarterly revenue was down 7.9% on a year-over-year basis. During the same period last year, the firm posted $0.38 EPS. On average, equities analysts anticipate that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider directly owned 18,985 shares in the company, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Inspire Medical Systems

Institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Inspire Medical Systems in the 2nd quarter worth approximately $211,341,000. Assenagon Asset Management S.A. raised its holdings in Inspire Medical Systems by 66.2% during the second quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock worth $38,561,000 after purchasing an additional 344,221 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Inspire Medical Systems by 21.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 546,020 shares of the company’s stock worth $24,358,000 after purchasing an additional 97,233 shares during the last quarter. Renaissance Technologies LLC boosted its position in Inspire Medical Systems by 14.4% during the first quarter. Renaissance Technologies LLC now owns 469,968 shares of the company’s stock worth $24,241,000 after purchasing an additional 59,200 shares in the last quarter. Finally, ADAR1 Capital Management LLC boosted its position in Inspire Medical Systems by 2,601.3% during the first quarter. ADAR1 Capital Management LLC now owns 405,197 shares of the company’s stock worth $20,900,000 after purchasing an additional 390,197 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter adjusted EPS of $0.14, above the $0.09 consensus estimate, while revenue of approximately $206.7 million also exceeded expectations of $204.3 million. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Robert W. Baird raised its price target to $77 from $73, while maintaining a neutral rating, implying substantial potential upside based on the current share price. Robert W. Baird Inspire Analyst Ratings
• Positive Sentiment: Piper Sandler increased its price target to $70 from $60 and kept a neutral rating, reflecting improved expectations despite continued uncertainty. Piper Sandler Inspire Analyst Ratings
• Neutral Sentiment: Management expects fiscal 2026 revenue of $850 million to $860 million and EPS of $1.20 to $1.40. The ranges broadly bracket analyst expectations, offering limited evidence of a meaningful upward revision.
• Neutral Sentiment: On the earnings call, Inspire projected low-single-digit revenue growth in 2027 as reimbursement and coding conditions stabilize. Stabilization is encouraging, but the growth outlook remains modest. Inspire Projects Low Single-Digit 2027 Revenue Growth
• Negative Sentiment: Third-quarter revenue declined 7.9% year over year and EPS fell from $0.38 to $0.14, highlighting ongoing operating pressure despite the quarterly consensus beat.
• Negative Sentiment: Barclays cut its price target to $62 from $65 and assigned an underweight rating, leaving little implied upside and reinforcing investor concerns about the company’s near-term growth profile. Barclays Inspire Analyst Ratings

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.